|
US3180193A
(en)
|
1963-02-25 |
1965-04-27 |
Benedict David |
Machines for cutting lengths of strip material
|
|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
JPS5612114B2
(enExample)
|
1974-06-07 |
1981-03-18 |
|
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
US4231938A
(en)
|
1979-06-15 |
1980-11-04 |
Merck & Co., Inc. |
Hypocholesteremic fermentation products and process of preparation
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
AU548996B2
(en)
|
1980-02-04 |
1986-01-09 |
Merck & Co., Inc. |
Tetrahydro-2h-pyran-2-one derivatives
|
|
US4444784A
(en)
|
1980-08-05 |
1984-04-24 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
DE3374837D1
(en)
|
1982-02-17 |
1988-01-21 |
Ciba Geigy Ag |
Lipids in the aqueous phase
|
|
JPS58166633A
(ja)
|
1982-03-29 |
1983-10-01 |
Toshiba Corp |
有機溶媒電池用正極
|
|
JPS58166634A
(ja)
|
1982-03-29 |
1983-10-01 |
Toshiba Corp |
有機溶媒電池用正極
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
DE3474511D1
(en)
|
1983-11-01 |
1988-11-17 |
Terumo Corp |
Pharmaceutical composition containing urokinase
|
|
US4740461A
(en)
|
1983-12-27 |
1988-04-26 |
Genetics Institute, Inc. |
Vectors and methods for transformation of eucaryotic cells
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
|
JPS62170639A
(ja)
|
1986-01-22 |
1987-07-27 |
株式会社システムメンテナンス |
防蟻板の取付け工法
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
US4959455A
(en)
|
1986-07-14 |
1990-09-25 |
Genetics Institute, Inc. |
Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
WO1988001649A1
(en)
|
1986-09-02 |
1988-03-10 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4912040A
(en)
|
1986-11-14 |
1990-03-27 |
Genetics Institute, Inc. |
Eucaryotic expression system
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
ES2087997T3
(es)
|
1990-01-12 |
1996-08-01 |
Cell Genesys Inc |
Generacion de anticuerpos xenogenicos.
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
FR2664073A1
(fr)
|
1990-06-29 |
1992-01-03 |
Thomson Csf |
Moyens de marquage d'objets, procede de realisation et dispositif de lecture.
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5789650A
(en)
|
1990-08-29 |
1998-08-04 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
WO1992003917A1
(en)
|
1990-08-29 |
1992-03-19 |
Genpharm International |
Homologous recombination in mammalian cells
|
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
ES2108048T3
(es)
|
1990-08-29 |
1997-12-16 |
Genpharm Int |
Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
|
|
WO1992022670A1
(en)
|
1991-06-12 |
1992-12-23 |
Genpharm International, Inc. |
Early detection of transgenic embryos
|
|
AU2235992A
(en)
|
1991-06-14 |
1993-01-12 |
Genpharm International, Inc. |
Transgenic immunodeficient non-human animals
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
JP2648897B2
(ja)
|
1991-07-01 |
1997-09-03 |
塩野義製薬株式会社 |
ピリミジン誘導体
|
|
WO1993004169A1
(en)
|
1991-08-20 |
1993-03-04 |
Genpharm International, Inc. |
Gene targeting in animal cells using isogenic dna constructs
|
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
|
ATE463573T1
(de)
|
1991-12-02 |
2010-04-15 |
Medimmune Ltd |
Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
|
|
EP1291360A1
(en)
|
1991-12-13 |
2003-03-12 |
Xoma Corporation |
Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
|
|
US5869619A
(en)
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
|
EP0746609A4
(en)
|
1991-12-17 |
1997-12-17 |
Genpharm Int |
NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
|
|
WO1994000569A1
(en)
|
1992-06-18 |
1994-01-06 |
Genpharm International, Inc. |
Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
|
|
JPH07509137A
(ja)
|
1992-07-24 |
1995-10-12 |
セル ジェネシス，インク． |
異種抗体の生産
|
|
US6066718A
(en)
|
1992-09-25 |
2000-05-23 |
Novartis Corporation |
Reshaped monoclonal antibodies against an immunoglobulin isotype
|
|
US5981175A
(en)
|
1993-01-07 |
1999-11-09 |
Genpharm Internation, Inc. |
Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
|
|
JPH08509612A
(ja)
|
1993-04-26 |
1996-10-15 |
ジェンファーム インターナショナル インコーポレイテッド |
異種抗体を産生することができるトランスジェニック非ヒト動物
|
|
US5625825A
(en)
|
1993-10-21 |
1997-04-29 |
Lsi Logic Corporation |
Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
|
|
US5643763A
(en)
|
1994-11-04 |
1997-07-01 |
Genpharm International, Inc. |
Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
|
|
CA2219486A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
ATE483733T1
(de)
|
1995-06-14 |
2010-10-15 |
Univ California |
Hochaffine humane antikörper gegen tumorantigene
|
|
US6127977A
(en)
|
1996-11-08 |
2000-10-03 |
Cohen; Nathan |
Microstrip patch antenna with fractal structure
|
|
EP0773288A3
(en)
|
1995-08-29 |
1997-07-09 |
Kirin Brewery |
Chimera animal and its method of manufacture
|
|
GB9610992D0
(en)
|
1996-05-24 |
1996-07-31 |
Glaxo Group Ltd |
Concentrated antibody preparation
|
|
AU4326197A
(en)
|
1996-07-09 |
1998-02-02 |
Merck & Co., Inc. |
Pharmaceutical compositions
|
|
EP0852951A1
(de)
|
1996-11-19 |
1998-07-15 |
Roche Diagnostics GmbH |
Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
|
|
EP2305027B1
(en)
|
1996-12-03 |
2014-07-02 |
Amgen Fremont Inc. |
Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
|
|
US6133426A
(en)
|
1997-02-21 |
2000-10-17 |
Genentech, Inc. |
Humanized anti-IL-8 monoclonal antibodies
|
|
US7411051B2
(en)
|
1997-03-07 |
2008-08-12 |
Human Genome Sciences, Inc. |
Antibodies to HDPPA04 polypeptide
|
|
US20070015696A1
(en)
|
1997-03-07 |
2007-01-18 |
Rosen Craig A |
621 human secreted proteins
|
|
US7968689B2
(en)
|
1997-03-07 |
2011-06-28 |
Human Genome Sciences, Inc. |
Antibodies to HSDEK49 polypeptides
|
|
US20070224663A1
(en)
|
1997-03-07 |
2007-09-27 |
Human Genome Sciences, Inc. |
Human Secreted Proteins
|
|
US20070055056A1
(en)
|
1997-03-07 |
2007-03-08 |
Rosen Craig A |
251 human secreted proteins
|
|
US20050197285A1
(en)
|
1997-03-07 |
2005-09-08 |
Rosen Craig A. |
Human secreted proteins
|
|
US20060223088A1
(en)
|
1997-03-07 |
2006-10-05 |
Rosen Craig A |
Human secreted proteins
|
|
US20060246483A1
(en)
|
1997-03-07 |
2006-11-02 |
Rosen Craig A |
337 human secreted proteins
|
|
US20060223090A1
(en)
|
1997-03-07 |
2006-10-05 |
Rosen Craig A |
Polynucleotides encoding human secreted proteins
|
|
US20080103090A1
(en)
|
1997-03-07 |
2008-05-01 |
Human Genome Sciences, Inc. |
Human Secreted Proteins
|
|
US7368531B2
(en)
|
1997-03-07 |
2008-05-06 |
Human Genome Sciences, Inc. |
Human secreted proteins
|
|
US20070059302A1
(en)
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
US6252050B1
(en)
|
1998-06-12 |
2001-06-26 |
Genentech, Inc. |
Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
US6833268B1
(en)
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
|
EP1514933A1
(en)
|
1999-07-08 |
2005-03-16 |
Research Association for Biotechnology |
Secretory protein or membrane protein
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
US20030119038A1
(en)
|
1999-09-09 |
2003-06-26 |
Bingham Brendan William |
NARC1, novel subtilase-like homologs
|
|
US7029895B2
(en)
|
1999-09-27 |
2006-04-18 |
Millennium Pharmaceuticals, Inc. |
27411, a novel human PGP synthase
|
|
US20100291099A1
(en)
|
1999-09-27 |
2010-11-18 |
Millennium Pharmaceuticals, Inc. |
Novel 27411, 23413, 22438, 23553, 25278, 26212, narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, narc 25, 86604 and 32222 molecules and uses therefor
|
|
JP2003512840A
(ja)
|
1999-10-22 |
2003-04-08 |
ミレニアム・ファーマシューティカルズ・インコーポレイテッド |
ラット脳に由来する核酸分子およびプログラム細胞死モデル
|
|
US20110230392A1
(en)
|
1999-10-22 |
2011-09-22 |
Millennium Pharmaceuticals, Inc. |
Novel narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, and narc 25 molecules and uses therefor
|
|
US20020081679A1
(en)
|
1999-10-22 |
2002-06-27 |
Millennium Pharmaceuticals, Inc. |
NARC8 programmed cell-death-associated molecules and uses thereof
|
|
CA2399727A1
(en)
|
2000-02-07 |
2001-08-09 |
Millennium Pharmaceuticals, Inc. |
Narc-1, subtilase-like homologs
|
|
JP2003533187A
(ja)
|
2000-05-03 |
2003-11-11 |
アムジエン・インコーポレーテツド |
治療薬としてのＦｃドメインを含む修飾ペプチド
|
|
AU2001269836A1
(en)
|
2000-06-16 |
2002-01-02 |
Incyte Genomics, Inc. |
Proteases
|
|
AU2001280471A1
(en)
|
2000-08-11 |
2002-02-25 |
Eli Lilly And Company |
Novel secreted proteins and their uses
|
|
PT1324776E
(pt)
|
2000-10-12 |
2009-12-23 |
Genentech Inc |
Formulações de proteína concentradas de viscosidade reduzida
|
|
AU2001295337A1
(en)
|
2000-10-20 |
2002-04-29 |
Ian Crandall |
E. histolytica-specific antibodies and clinical uses thereof
|
|
CA2436732A1
(en)
|
2000-12-08 |
2002-06-13 |
Incyte Genomics, Inc. |
Protein modification and maintenance molecules
|
|
EP1414845A4
(en)
|
2001-03-21 |
2009-07-08 |
Human Genome Sciences |
SEPARATE HUMAN PROTEINS
|
|
US20040023243A1
(en)
|
2001-06-13 |
2004-02-05 |
Yue Henry |
Proteases
|
|
CA2450793A1
(en)
|
2001-06-20 |
2002-12-27 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
US20040038242A1
(en)
|
2001-07-30 |
2004-02-26 |
Edmonds Brian Taylor |
Novel secreted proteins and their uses
|
|
WO2003041684A2
(en)
*
|
2001-11-14 |
2003-05-22 |
Alza Corporation |
Injectable depot compositions and uses thereof
|
|
EP1572903A2
(en)
|
2002-02-11 |
2005-09-14 |
Alexion Pharmaceuticals, Inc. |
Immunotherapeutics for biodefense
|
|
WO2004017986A1
(en)
|
2002-08-23 |
2004-03-04 |
Valorisation-Recherche, Societe En Commandite |
Growth hormone-releasing peptides in the treatment of prevention of atherosclerosis and hypercholesterolemia
|
|
US6875433B2
(en)
|
2002-08-23 |
2005-04-05 |
The United States Of America As Represented By The Secretary Of The Army |
Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
|
|
ME00204B
(me)
|
2002-09-06 |
2011-02-10 |
Medarex Llc |
Terapijsko, humano, monoklonsko anti-il-1r1antitijelo
|
|
AR047392A1
(es)
|
2002-10-22 |
2006-01-18 |
Wyeth Corp |
Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
|
|
AU2003293543A1
(en)
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
|
US20050158303A1
(en)
|
2003-04-04 |
2005-07-21 |
Genentech, Inc. |
Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
|
|
EP1471152A1
(en)
|
2003-04-25 |
2004-10-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Mutations in the human PCSK9 gene associated to hypercholesterolemia
|
|
MXPA05012571A
(es)
|
2003-05-21 |
2006-02-08 |
Medarex Inc |
Anticuerpos monoclonales humanos contra el antigeno protector de bacillus anthracis.
|
|
US20050118625A1
(en)
|
2003-10-02 |
2005-06-02 |
Mounts William M. |
Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
|
|
JP2005130764A
(ja)
|
2003-10-30 |
2005-05-26 |
Pharmaceuticals & Medical Devices Agency |
Ｎａｒｃ−１遺伝子上の多型を利用した脂質代謝異常に起因する疾患の検査方法、および創薬のための用途
|
|
CN1897918A
(zh)
|
2003-11-17 |
2007-01-17 |
阿尔萨公司 |
包含两亲性分子作为混悬载体的组合物和剂型
|
|
CA2559889A1
(en)
|
2004-01-16 |
2005-08-25 |
Barnes-Jewish Hospital |
Targeted atherosclerosis treatment
|
|
PT2409713E
(pt)
|
2004-08-10 |
2015-10-09 |
Genzyme Corp |
Oligonucleótidos para utilização em modulação dos níveis de lipoproteínas e colesterol em humanos
|
|
US20060147945A1
(en)
|
2005-01-06 |
2006-07-06 |
Edmonds Brian T |
Novel secreted proteins and their uses
|
|
CA2589860A1
(en)
|
2005-01-24 |
2006-08-03 |
Amgen Inc. |
Humanized anti-amyloid antibody
|
|
WO2006124269A2
(en)
|
2005-05-16 |
2006-11-23 |
Amgen Fremont Inc. |
Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
|
|
ES2776657T3
(es)
|
2005-06-14 |
2020-07-31 |
Amgen Inc |
Formulaciones de proteínas autotamponantes
|
|
EP1940881B1
(en)
|
2005-10-11 |
2016-11-30 |
Amgen Research (Munich) GmbH |
Compositions comprising cross-species-specific antibodies and uses thereof
|
|
US8304383B2
(en)
|
2005-11-22 |
2012-11-06 |
Atheronova Operations, Inc. |
Dissolution of arterial plaque
|
|
EP1977763A4
(en)
*
|
2005-12-28 |
2010-06-02 |
Chugai Pharmaceutical Co Ltd |
ANTIBODY-CONTAINING STABILIZING PREPARATION
|
|
CA2637837A1
(en)
|
2006-01-26 |
2007-08-09 |
Hx Diagnostics, Inc. |
Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
|
|
CA2900402C
(en)
|
2006-05-08 |
2018-01-16 |
Adaerata, Limited Partnership |
Pcsk9 polypeptide, ligand to said polypeptide, kits and methods using said ligands
|
|
EP2194128B1
(en)
|
2006-05-11 |
2012-08-01 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of the PCSK9 gene
|
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
|
US7737266B2
(en)
|
2006-09-18 |
2010-06-15 |
Board Of Regents, The University Of Texas System |
RNAi modulation of SCAP and therapeutics uses thereof
|
|
US20100068194A1
(en)
|
2006-10-24 |
2010-03-18 |
Dong-Ku Kim |
Composition for in vivo transplantation for treatment of human cervical cancer comprising mononuclear cells derived from umbilical cord blood
|
|
CA2667989A1
(en)
|
2006-11-07 |
2008-11-06 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
|
WO2008057458A2
(en)
|
2006-11-07 |
2008-05-15 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
|
WO2008057457A2
(en)
|
2006-11-07 |
2008-05-15 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
|
EP2083861A4
(en)
|
2006-11-07 |
2010-11-24 |
Merck Sharp & Dohme |
ANTAGONISTS OF PCSK9
|
|
FR2909092B1
(fr)
|
2006-11-24 |
2012-10-19 |
Pf Medicament |
Nouveaux anticorps anti-proliferation
|
|
EP2114451A2
(en)
*
|
2007-01-09 |
2009-11-11 |
Wyeth a Corporation of the State of Delaware |
Anti-il-13 antibody formulations and uses thereof
|
|
WO2008109871A2
(en)
|
2007-03-08 |
2008-09-12 |
Irm Llc |
Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof
|
|
AU2008232903B9
(en)
*
|
2007-03-30 |
2013-09-05 |
Medimmune Llc |
Antibodies with decreased deamidation profiles
|
|
WO2008125623A2
(en)
|
2007-04-13 |
2008-10-23 |
Novartis Ag |
Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
|
|
US8975377B2
(en)
|
2007-08-13 |
2015-03-10 |
Vasgene Therapeutics, Inc |
Cancer treatment using humanized antibodies that bind to EphB4
|
|
EP2615114B1
(en)
|
2007-08-23 |
2022-04-06 |
Amgen Inc. |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
|
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
|
US20130072665A1
(en)
|
2007-08-23 |
2013-03-21 |
Simon Mark Jackson |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
|
|
US8623650B2
(en)
|
2007-10-19 |
2014-01-07 |
Viacyte, Inc. |
Methods and compositions for feeder-free pluripotent stem cell media containing human serum
|
|
SG2013014352A
(en)
*
|
2007-10-26 |
2014-09-26 |
Merck Sharp & Dohme |
Anti-pcsk9 and methods for treating lipid and cholesterol disorders
|
|
MX2010008688A
(es)
|
2008-02-07 |
2010-08-30 |
Schering Corp |
Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria.
|
|
AR070316A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
|
AR070315A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Anticuerpos 1b20 antagonistas de pcsk9
|
|
TWI700293B
(zh)
|
2008-04-11 |
2020-08-01 |
日商中外製藥股份有限公司 |
重複結合複數個抗原的抗體
|
|
WO2009131740A2
(en)
|
2008-04-23 |
2009-10-29 |
Amgen Inc. |
Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
|
|
US20090275053A1
(en)
|
2008-04-30 |
2009-11-05 |
Board Of Regents, The University Of Texas System |
Cell-based pcsk9 screening assay
|
|
DK2982695T3
(da)
|
2008-07-09 |
2019-05-13 |
Biogen Ma Inc |
Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
|
|
ES2808660T3
(es)
|
2008-08-04 |
2021-03-01 |
Amgen Inc |
Proteínas de unión a antígeno para proproteína convertasa subtilisina kexina tipo 9 (PCSK9)
|
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Ｐｃｓｋ９拮抗劑類
|
|
EP2362767B1
(en)
*
|
2008-10-29 |
2017-12-06 |
Ablynx N.V. |
Formulations of single domain antigen binding molecules
|
|
WO2010068526A1
(en)
|
2008-12-12 |
2010-06-17 |
Merck Sharp & Dohme Corp. |
Pcsk9 immunoassay
|
|
US8357371B2
(en)
|
2008-12-15 |
2013-01-22 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to PCSK9
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
CL2011001435A1
(es)
|
2008-12-15 |
2012-02-24 |
Regeneron Pharma |
Anticuerpo humano que se une especificamente a la proteina convertasa subtilisina/kexuba/kexina de tipo 9 humana (hpcsk9) o fragmento de union a antigeno del mismo; molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica; y su uso para tratar una enfermedad relacionada con hpcsk9.
|
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
|
AU2010221156A1
(en)
|
2009-03-06 |
2011-09-22 |
Genentech, Inc. |
Antibody formulation
|
|
EP2456870A1
(en)
|
2009-07-21 |
2012-05-30 |
Santaris Pharma A/S |
Antisense oligomers targeting pcsk9
|
|
WO2011028938A1
(en)
*
|
2009-09-02 |
2011-03-10 |
Alnylam Pharmaceuticals, Inc. |
Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
|
|
WO2011037791A1
(en)
|
2009-09-25 |
2011-03-31 |
Merck Sharp & Dohme Corp. |
Antagonists of pcsk9
|
|
WO2011053665A1
(en)
|
2009-10-30 |
2011-05-05 |
Merck Sharp & Dohme Corp. |
Pcsk9 immunoassay
|
|
WO2011053759A1
(en)
|
2009-10-30 |
2011-05-05 |
Merck Sharp & Dohme Corp. |
Ax1 and ax189 pcsk9 antagonists and variants
|
|
EP2493507A4
(en)
|
2009-10-30 |
2013-11-20 |
Merck Sharp & Dohme |
AX213 AND AX132 PCSK9 ANTAGONISTS AND VARIANTS THEREOF
|
|
EP2494355A4
(en)
|
2009-10-30 |
2013-05-01 |
Merck Sharp & Dohme |
PCSK9 IMMUNOASSAY
|
|
PT3721904T
(pt)
|
2009-11-20 |
2021-11-15 |
Biocon Ltd |
Formulações de anticorpo t1h
|
|
AR079336A1
(es)
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
|
EA031209B9
(ru)
|
2010-01-15 |
2021-11-19 |
Кирин-Эмджен, Инк. |
Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения
|
|
US20110207759A1
(en)
|
2010-02-19 |
2011-08-25 |
Taylor Allen John |
Method for treatment of atherosclerotic disease
|
|
WO2011109415A2
(en)
*
|
2010-03-02 |
2011-09-09 |
Amgen Inc. |
Reducing viscosity of pharmaceutical formulations
|
|
EP2545079A2
(en)
|
2010-03-11 |
2013-01-16 |
Rinat Neuroscience Corporation |
ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
|
|
KR20130056871A
(ko)
|
2010-04-13 |
2013-05-30 |
브리스톨-마이어스 스큅 컴퍼니 |
Ｐｃｓｋ９에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질
|
|
CN201712554U
(zh)
|
2010-07-14 |
2011-01-19 |
李辉 |
电动汽车热管理系统
|
|
WO2012054438A1
(en)
|
2010-10-22 |
2012-04-26 |
Schering Corporation |
Anti-pcsk9
|
|
CA2820953A1
(en)
|
2010-12-22 |
2012-06-28 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
|
EP2481758A1
(en)
|
2011-01-28 |
2012-08-01 |
Sanofi |
Human antibodies to PSCK9 for use in methods of treating particular groups of subjects (11566)
|
|
EP2650016A1
(en)
|
2011-01-28 |
2013-10-16 |
Sanofi |
Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
|
|
BR112013018740A2
(pt)
|
2011-01-28 |
2019-01-08 |
Sanofi Sa |
anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos
|
|
WO2012109097A1
(en)
|
2011-02-10 |
2012-08-16 |
Trustees Of Dartmouth College |
Methods for increasing plasmin activity and promoting plaque regression in the treatment of atherosclerosis
|
|
CN103562227B
(zh)
|
2011-02-11 |
2016-12-21 |
诺瓦提斯公司 |
Pcsk9拮抗剂
|
|
US20140004122A1
(en)
|
2011-05-10 |
2014-01-02 |
Amgen Inc. |
Methods for treating or preventing cholesterol related disorders
|
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
|
WO2012170607A2
(en)
|
2011-06-10 |
2012-12-13 |
Novartis Ag |
Use of pcsk9 antagonists
|
|
WO2012168491A1
(en)
|
2011-06-10 |
2012-12-13 |
Novartis Ag |
Pharmaceutical formulations of pcsk9 antagonists
|
|
RU2014101501A
(ru)
|
2011-06-20 |
2015-07-27 |
Дженентек, Инк. |
Связывающие pcsk9 полипептиды и способы применения
|
|
CA2840482C
(en)
|
2011-07-14 |
2018-10-16 |
Pfizer Inc. |
Treatment with anti-pcsk9 antibodies
|
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
AR087715A1
(es)
|
2011-09-16 |
2014-04-09 |
Lilly Co Eli |
Anticuerpos anti pcsk9 y usos de los mismos
|
|
CN103930444B
(zh)
|
2011-09-16 |
2020-08-04 |
瑞泽恩制药公司 |
用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
|
|
US9879093B2
(en)
|
2011-12-20 |
2018-01-30 |
Adaerata, Limited Partnershp |
Single domain antibodies as inhibitors of PCSK9
|
|
WO2013148284A1
(en)
|
2012-03-29 |
2013-10-03 |
Genentech, Inc. |
Antibodies that bind to a pcsk9 cleavage site and methods of use
|
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
|
US9255154B2
(en)
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
|
US9401875B2
(en)
|
2012-06-01 |
2016-07-26 |
Nippon Telegraph And Telephone Corporation |
Packet transfer processing method and packet transfer processing device
|
|
JP2015530867A
(ja)
|
2012-06-15 |
2015-10-29 |
ジェネンテック， インコーポレイテッド |
抗ｐｃｓｋ９抗体、製剤、投薬、及び使用方法
|
|
EP2703009A1
(en)
|
2012-08-31 |
2014-03-05 |
Sanofi |
Combination treatments involving antibodies to human PCSK9
|
|
EP2706070A1
(en)
|
2012-09-06 |
2014-03-12 |
Sanofi |
Combination treatments involving antibodies to human PCSK9
|
|
SI2922875T1
(sl)
|
2012-11-20 |
2017-06-30 |
Sanofi |
Protitelesa anti-CEACAM5 in njihove uporabe
|
|
EP2970501A2
(en)
|
2013-03-15 |
2016-01-20 |
Amgen, Inc. |
Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
|
|
JP6071725B2
(ja)
|
2013-04-23 |
2017-02-01 |
カルソニックカンセイ株式会社 |
電気自動車の駆動力制御装置
|
|
EP2862877A1
(en)
|
2013-10-18 |
2015-04-22 |
Sanofi |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
|
WO2014209384A1
(en)
|
2013-06-28 |
2014-12-31 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolema
|
|
US20150004174A1
(en)
|
2013-06-28 |
2015-01-01 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
|
CN114642661A
(zh)
|
2014-03-17 |
2022-06-21 |
赛诺菲生物技术公司 |
用于降低心血管风险的方法
|
|
US9300829B2
(en)
|
2014-04-04 |
2016-03-29 |
Canon Kabushiki Kaisha |
Image reading apparatus and correction method thereof
|
|
JP6783223B2
(ja)
|
2014-07-14 |
2020-11-11 |
アムジェン インコーポレイテッド |
結晶性抗体製剤
|
|
KR20230074283A
(ko)
|
2014-07-16 |
2023-05-26 |
사노피 바이오테크놀로지 |
이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
|
|
WO2016046684A1
(en)
|
2014-09-23 |
2016-03-31 |
Pfizer Inc. |
Treatment with anti-pcsk9 antibodies
|
|
US10254272B2
(en)
|
2015-01-09 |
2019-04-09 |
Global Genomics Group, LLC |
Blood based biomarkers for diagnosing atherosclerotic coronary artery disease
|
|
GB201510758D0
(en)
|
2015-06-18 |
2015-08-05 |
Ucb Biopharma Sprl |
Novel TNFa structure for use in therapy
|
|
JP2018523684A
(ja)
|
2015-08-18 |
2018-08-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
|
|
JOP20190112A1
(ar)
|
2016-11-14 |
2019-05-14 |
Amgen Inc |
علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
|
|
JP7377596B2
(ja)
|
2017-02-22 |
2023-11-10 |
アムジエン・インコーポレーテツド |
低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
|
|
US11284893B2
(en)
|
2019-04-02 |
2022-03-29 |
Covidien Lp |
Stapling device with articulating tool assembly
|
|
AR122180A1
(es)
|
2020-05-29 |
2022-08-24 |
Amgen Inc |
Métodos de uso de inhibidores de pcsk9 para tratar trastornos relacionados con el colesterol ldl
|